Search
Oritavancin
go.drugbank.com/drugs/DB04911ApprovedInvestigationalIt boasts the option of single-dose administration and has been proven as non-inferior to a full course of [vancomycin] therapy. … It was developed by The Medicines Company (acquired by Novartis).
TrenibotulinumtoxinE
go.drugbank.com/drugs/DB19082Approved[L64095] TrenibotulinumtoxinE is distinguished from the serotype A toxins that dominate this setting by its rapid onset and short duration: effects begin around 8 hours after injection, peak at day 7, … [L64095,L64118] It is given as an intramuscular injection into the corrugator and procerus muscles, is intended for occasional use, and its potency units are not interchangeable with those of other botulinum
Doxofylline
go.drugbank.com/drugs/DB09273InvestigationalAs a drug used in the treatment of asthma, doxofylline has shown similar efficacy to theophylline but with significantly fewer side effects in animal and human studies. … Unlike theophylline, doxofylline does not affect calcium influx and does not antagonize the actions of calcium channel blockers which could explain reduced cardiac adverse reactions associated with the
Deoxycholic acid
go.drugbank.com/drugs/DB03619ApprovedInvestigationalIt is marketed under the brand name Kybella by Kythera Biopharma and is the first pharmacological agent available for submental fat reduction, allowing for a safer and less invasive alternative than surgical … In April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve aesthetic appearance and reduce facial fullness or convexity.
Amiloride
go.drugbank.com/drugs/DB00594ApprovedInvestigationalA pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and c...
Synonyms: N-amidino-3,5-diamino-6-chloropyrazinecarboxamide, 3,5-diamino-N-carbamimidoyl-6-chloropyrazine-2-carboxamideMixtures: Nu-amilzide 5/50 Mg TabRipretinib
go.drugbank.com/drugs/DB14840ApprovedInvestigationalRipretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020. … Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and [imatinib]
Tolazamide
go.drugbank.com/drugs/DB00839ApprovedA sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.
Synonyms: N-(p-Toluenesulfonyl)-N'-hexamethyleniminoureaSiltuximab
go.drugbank.com/drugs/DB09036ApprovedInvestigationalSiltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. … Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6).
Flucloxacillin
go.drugbank.com/drugs/DB00301ApprovedInvestigationalWithdrawnAntibiotic analog of cloxacillin.
Nifurtimox
go.drugbank.com/drugs/DB11820ApprovedInvestigationalIf Chagas disease is left untreated, life-threatening sequelae may result.[L15366] Nifurtimox, developed by Bayer, is a nitrofuran antiprotozoal drug used in the treatment of Chagas disease. … Chagas disease, caused by a parasite known as Trypanosoma cruzi (T.cruzi), is a vector-transmitted disease affecting animals and humans in the Americas.